- Home
- EXEL vs SIGA Comparison
EXEL vs SIGA Comparison
Compare EXEL & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- SIGA
- Stock Information
- Founded
- EXEL 1994
- SIGA 1995
- Country
- EXEL United States
- SIGA United States
- Employees
- EXEL N/A
- SIGA N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- SIGA Health Care
- Exchange
- EXEL Nasdaq
- SIGA Nasdaq
- Market Cap
- EXEL 9.8B
- SIGA N/A
- IPO Year
- EXEL 2000
- SIGA 1997
- Fundamental
- Price
- EXEL $36.50
- SIGA $5.44
- Analyst Decision
- EXEL Buy
- SIGA
- Analyst Count
- EXEL 18
- SIGA 0
- Target Price
- EXEL $37.59
- SIGA N/A
- AVG Volume (30 Days)
- EXEL 2.3M
- SIGA 579.6K
- Earning Date
- EXEL 05-13-2025
- SIGA 05-08-2025
- Dividend Yield
- EXEL N/A
- SIGA 11.03%
- EPS Growth
- EXEL 170.77
- SIGA N/A
- EPS
- EXEL 1.76
- SIGA 0.82
- Revenue
- EXEL $2,168,701,000.00
- SIGA $138,719,350.00
- Revenue This Year
- EXEL $5.78
- SIGA N/A
- Revenue Next Year
- EXEL $10.94
- SIGA $95.35
- P/E Ratio
- EXEL $20.74
- SIGA $6.40
- Revenue Growth
- EXEL 18.50
- SIGA N/A
- 52 Week Low
- EXEL $20.14
- SIGA $4.95
- 52 Week High
- EXEL $40.26
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- EXEL 45.67
- SIGA 42.98
- Support Level
- EXEL $35.34
- SIGA $5.21
- Resistance Level
- EXEL $40.26
- SIGA $5.64
- Average True Range (ATR)
- EXEL 1.21
- SIGA 0.21
- MACD
- EXEL -0.09
- SIGA -0.09
- Stochastic Oscillator
- EXEL 29.79
- SIGA 16.43
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.